Skip to content

FDA Announces “RAPID” Pathway for Expedited Access to Breakthrough Devices by Medicare Population

 | 

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced “a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare.” The FDA announcement for the pathway, titled Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, can be found here.

The announcement indicates Class II devices may be eligible for the new pathway if they are participating in the FDA Total Product Life Cycle Advisory Program (TAP), and Class III devices may be eligible regardless of participation in TAP. The FDA announcement also indicates that “[t]o be eligible for the RAPID coverage pathway, devices must be the subject of an Investigational Device Exemption (IDE) study that enrolls Medicare beneficiaries and studies clinical health outcomes agreed upon by the FDA and CMS.”

The RAPID coverage pathway is intended to accelerate access to breakthrough devices by (1) promoting early alignment between the CMS, FDA, and innovators, and (2) establishing a predictable timeline and process.

The FDA announcement states:

This streamlined approach could enable predictable Medicare national coverage and payment as soon as two months after market authorization, compared to approximately a year or more under the current pathway . . .

The FDA expects early coordination between the relevant parties will allow for alignment of premarket evidence for both FDA premarket review and Medicare coverage processes. “Aligning evidence expectations earlier reduces duplication, improves efficiency, and provides increased transparency to innovators,” the announcement states.

The RAPID coverage pathway intends to provide benefits to all parties involved, including “increasing transparency, predictability, and cost savings” for innovators of the breakthrough devices.

For those interested in the RAPID coverage pathway, be on the lookout for a procedural notice in the Federal Register. Once published, the notice will allow the public 60 days to provide comments.

Tags

, ,

FDA Announces “RAPID” Pathway for Expedited Access to Breakthrough Devices by Medicare Population Headshot

Paige L. Cappelli

Paige Cappelli primarily focuses on patent prosecution and patent litigation in the mechanical and medical device areas. Paige graduated magna cum laude from Temple University Beasley School of Law. While...

View all posts published by Paige L. Cappelli
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal